title: Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12-13 February 2009.
abstract: Influenza vaccines are potentially the most efficacious means of mitigating the impact of influenza pandemic and might contribute to the rapid containment of an emerging pandemic virus. On the 12-13 February 2009, the Initiative For Vaccine Research (IVR) of the World Health Organisation convened the 5th meeting on the 'Evaluation of pandemic influenza prototype vaccines in clinical trials' in Geneva. This was a follow-up meeting to the 4th meeting held on 14-15 February 2008 [Girard M, Palkonyay L, Kieny MP. Report of the 4th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials. Vaccine 2008;26:4975-7], and presentations were made by representatives from industry, academia, and governmental organisations. This year's meeting aimed to update the progress made during the past year on H5N1 and other prototype pandemic vaccines that have undergone clinical trials. A number of vaccine types were covered, including classical egg-derived inactivated vaccines, cell-derived inactivated vaccines, live-attenuated vaccines (LAIV) and vaccines developed using new technologies. The effects of different adjuvants and prime-boosting schedules were important topics, and further data were presented to show that children mount vigorous antibody responses to several H5N1 vaccines. Other subjects presented and discussed were standardisation, and regulatory issues concerning pandemic vaccines.
authors.affiliation: International Activities-Science Funding, The Wellcome Trust, 215 Euston Road, London NW1 2BE, United Kingdom.
authors.forename: Frederick G
authors.initials: FG
authors.lastname: Hayden
authors.forename: Wendy A
authors.initials: WA
authors.lastname: Howard
authors.forename: Laszlo
authors.initials: L
authors.lastname: Palkonyay
authors.forename: Marie Paule
authors.initials: MP
authors.lastname: Kieny
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology; D004196:Disease Outbreaks / Q000517:prevention & control*; D006801:Humans; D053124:Influenza A Virus, H5N1 Subtype / Q000276:immunology; D007252:Influenza Vaccines / Q000276:immunology*; D007251:Influenza, Human / Q000453:epidemiology* / Q000517:prevention & control*; D013557:Switzerland; D014613:Vaccines, Attenuated / Q000276:immunology; D015164:Vaccines, Inactivated / Q000276:immunology; D014944:World Health Organization
chemical_list: D000276:Adjuvants, Immunologic; D007252:Influenza Vaccines; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated